Background: Polymerized allergoids coupled to nonoxidized mannan (PM-allergoids)
for treating respiratory allergies. 1 Safety is the main advantage for SLIT, given that systemic allergic reactions are very rare; yet, oral side effects are frequent and invariably occur in more than 50% of the patients receiving SLIT. 2 Although mild and self-limited, these aspects make compliance more difficult to achieve, especially in children. 3 Different meta-analysis seems to indicate that SLIT has lower clinical efficacy than SCIT, but these data are only based on indirect evidence and not on head-to-head comparisons. 4, 5 The immunologic mechanisms underlying the action of SLIT are less well established than SCIT, but similar immunomodulatory pathways have been described. 6, 7 In this regard, both therapies are thought to modulate the allergen-specific T-cell and B-cell responses similarly, including the generation of both regulatory T (Treg) and B (Breg) cells. [8] [9] [10] Allergen uptake by oral mucosal dendritic cells (DCs) is thought to be a critical step for initiating the immune response in SLIT, 11 a step requiring higher allergen concentration and dose frequency for SLIT than SCIT. 12 To improve allergen uptake by oral DCs, some experimental allergen formulations have been assayed, such as conjugation with cholera toxin, 13 binding to mucoadhesive agents, 14 or using nanoparticles. 15 We previously reported that polymerized allergoids coupled to nonoxidized mannan derived from Saccharomyces cerevisae (PM-allergoids) are better captured than native allergens by human 16 and canine 17 DCs. PM-allergoids are taken up by DCs very rapidly through a receptor-mediated mechanism involving C-type lectin receptors. 16 Besides their better uptake, these glycoconjugates are rendered hypoallergenic [16] [17] [18] 
| Allergen preparations
Grass pollen (Phleum pratense) allergens and mannan (Saccharomyces cerevisae) were obtained and purified as described. 18 Unmodified native allergens (N) were coupled to nonoxidized mannan (1:0.5 ratio) exactly as described 18 to render polymerized allergoid-mannan complexes (PM). For control purposes, PM-allergoids were further oxidized (PM-OX) with sodium periodate as described. 16 
| Immunization protocols
Mice (groups of 6 animals) were immunized sublingually with each allergen preparation (N, PM, or PM-OX) using three different 
| Antibody measurement
Specific antibodies against the native allergens (N) were measured by ELISA in each mouse serum. IgG1, IgG2a, and IgE antibodies were determined using appropriate anti-mouse isotype labeled antibodies (BD Pharmingen).
| Cell proliferation and cytokine measurement
Spleens and submandibular LNs were isolated aseptically, minced, and filtered through sterile steel filters. Erythrocyte-free cells were stained with 2 lM carboxyfluorescein succinimidyl ester as described. The cell suspensions were cultured into 24-well plates at a concentration of The data were analyzed using the FLOWJO V.10 software. 
| Treg cells measurement

| Isolation of antigen-presenting cells from the sublingual mucosa
Antigen-presenting cells were obtained following the protocol described by Tanaka et al. 20 Briefly, the mouse sublingual mucosa tissues were excised by trimming off the roots of the tongue and cut into fragments. Tissues were treated with 0.25% trypsin and 1 mM EDTA for 1 hours at 37⁰C with shaking. Next, they were incubated (1 hours at 37⁰C with shaking) with 1 mg/mL collagenase (Wako Pure Chemical) and 0.1 mg/mL DNase I (Sigma-Aldrich) in RPMI medium containing 10% fetal bovine serum. Cells were then filtered, using a 70-mm cell strainer. After washing, cells were purified by density gradient cen- 
| Statistics
Data are expressed as mean AE SEM of the indicated parameters.
Statistical differences were determined with the paired or unpaired Student's t test. Significance was defined as *P < .05, **P < .01, and ***P < .001.
3 | RESULTS
| Sublingual immunization with PM-allergoids
induces a quicker and stronger antibody response with a higher IgG2a/IgE ratio than native allergens
Three different protocols were used to immunize mice by the sublingual route differing in duration, frequency, and number of doses administered ( Figure 1A ). The immune responses were analyzed as indicated in Figure 1B .
Antibody serum levels to native Phleum pratense pollen extract were measured in sublingually immunized mouse sera 1 week after the last dose. As shown in Figure 2A , mice immunized with PMallergoids had a significant higher IgG1 and IgG2a levels than those immunized with native allergens using the shorter protocol (Protocol 1). This was also the case for IgG2a when using the intermediate protocol (Protocol 2). By contrast, using the longest protocol (Protocol 3), both IgG1-and IgE-specific antibody levels were significantly SORIA ET AL. 
produces a higher antigen-specific proliferative cell response in submandibular LNs and spleen than native allergens, with a higher ratio of IFNc/IL-4 production and a quicker IL-10 response
The in vitro proliferative activity of submandibular LN and spleen cells in response to native Phleum pratense pollen allergens was assessed in mice immunized sublingually with each allergen preparation. As shown in Figure 3 ( Figure S1 for Protocol 2), the lymphoproliferative response in mice immunized with PM-allergoids (but not with PM-OX) was always significantly higher than that obtained when immunizing with native allergens. Remarkably, in the spleen, a proliferative response above the nonimmunized control mice was only seen when using PM-allergoids ( Figure 3B ). Figure S1 ). This was accompanied by a lower IL-4 production, and therefore, a significant higher IFNc/IL-4 ratio was seen in mice treated with PM-allergoids using Results are the mean AE SEM of 6 mice. Statistical differences were analyzed with Student's t test. *P < .05, **P < .01, ***P < .001
Protocol 3 ( Figure 4B ). This ratio was always higher in submandibular LNs from mice immunized with PM-allergoids as well ( Figure 4A ).
Regarding IL-10 production, it was significantly higher when testing submandibular LN cells derived from mice immunized with PM-allergoids using the shorter Protocol 1 ( Figure 4A ). Once again, the above differences on cytokine production obtained when immunizing mice with PM-allergoids were completely lost if using PM-OX instead ( Figure 4 ). . Statistical differences were analyzed with Student's t test. *P < .05, **P < .01, ***P < .001
for the immunization through the sublingual route. 23 Supporting this route also for PM-allergoids is the response obtained in submandibular LNs, the primary draining lymph nodes of sublingual tissue. 24 In this sense, besides antigen penetration across the sublingual epithelial barrier, an active capture by intraepithelial DCs 25 or through the ductal epithelial cells 26 has been described, even for particulate antigens, silica beads, or microbes. 26 In fact, bigger structures than PMallergoids, like particles of different sizes 15, 27 or whole cell bacteria, 28, 29 have also been successfully used for immunization through the sublingual route.
The results also show that the main immunomodulatory features of PM-allergoids are greatly dependent on keeping the structural integrity of mannan. We previously demonstrated that PM-allergoids are much better captured than native allergens by human 16 and canine 17 DCs and that this property is lost upon mannan oxidation.
Here we show that this is also the case in mice when assessing anti- Among them, CD64 + cells were the most abundant (around 75%).
CD64, one of the most specific macrophage markers, 30 has been shown useful in discriminating macrophages from conventional CD11b + DCs. 31 The latter (CD11b + DCs) were about 15% of total CD45 + MHC-II + cells, whereas CD207 + Langerhans cells was a minor population (less than 5%) in our cell sample. These percentages fit well with those described by Tanaka et al in sublingual and lingual tissues when using a similar protocol for isolating antigen-presenting cells. 20 Interestingly, most of CD11b + DCs were able to capture PMallergoids, but only a minor part of CD64 + macrophages did so. Both cell subsets showed a quite similar increase in their capacity to uptake PM-allergoids in comparison with native allergens. Thus, our results suggest that, likely due to a better uptake, both myeloid cells might be involved in the superior response of mice immunized with PM-allergoids than native allergens, including the induction of Treg cells (see below).
Several mechanisms have been proposed for allergen uptake by DCs in SLIT, including the capture through specific IgE bound to FceRI on oral Langerhans cells, a major DC population within the oral mucosa in human beings. 25 In the case of PM-allergoids, however, their low IgE binding reactivity [16] [17] [18] would make this mechanism unlikely. Nevertheless, other IgE-independent mechanisms for allergen uptake have been described further, like CD207 (Langerin), a putative mannose receptor, 32, 33 or CD209 (DC-SIGN). 34 Previously, we have shown that the enhanced uptake of PM-allergoids by human and CD209 (DC-SIGN). 16 These receptors have been described in oral DCs as well, 35 including the CD11b + cells involved in tolerance induction during SLIT. 21 Interestingly, IL-4 may increase the expression of the mannose receptor on myeloid cells, 36 a fact already reported in DCs from allergy patients, 37 thus opening the possibility of even a better uptake of PM-allergoids in these patients. A relevant point of the present study is that the cells used for allergen uptake were resident cells obtained directly from the oral mucosa in a steady-state situation. Thus, it appears that PM-allergoids are better uptaken by either resident DCs or monocyte-derived DCs. 16, 17 DCs are the main initiators of immune responses with an important role in the polarization of naive T cells. 38 It is widely accepted that the efficiency of allergen-specific T-cell responses during allergen immunotherapy correlates with the capability of this therapy for skewing DCs. 39 We have shown that PM-allergoids promote the generation of Th1 and Treg cells in vitro, but also in vivo upon subcutaneous immunization in mice. 16 Here we show that similar responses might be induced by the sublingual route, which is evidenced by SLIT. 40 These cells may migrate from regional lymphoid organs or induced within the oral mucosa through local DC-T cell interaction. 40 Interestingly, an increase in Treg cells in submandibular LNs following SLIT has been described with antigen formulations that presumably facilitates the allergen capture by oral DCs. 13, 27 In this sense, anti- It has been suggested that an ideal allergen vaccine would target
DCs, yet not be recognized by mast cell surface IgE. 40 Mastocytes are abundant in the sublingual mucosa, and their activation through IgE is thought to account for the frequent local side effects during SLIT. 40, 42 In this sense, PM-allergoids have the advantage over the native allergens that show a very limited reactivity with specific IgE [16] [17] [18] and very low ability to activate skin mastocytes or blood basophils from Statistical differences were analyzed with Student's t test. **P < .01, ***P < .001 sensitized patients. 16 In addition, PM-allergoids may not directly activate human basophils as, unlike DCs, they do not express DC-SIGN and mannose receptors. 43 Taken together, polymerized allergoids coupled to nonoxidized mannan may be suitable candidates for the development of improved SLIT vaccines targeting DCs. 
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